You'll sleep better with up to AU$789 off Sleeping Duck's EOFY bed bundle deal
It's nearing the end of EOFY sales here in Australia, and plenty of great discounts come to a close once we say goodnight on June 30. But if you're after a brand new bed frame or mattress, you don't have to scramble to the shops just yet.
Renowned in the bed-in-a-box space, Sleeping Duck currently claims the top spot in our best mattresses in Australia guide, and for good reason. Offering a 100-night trial window, firmness customisation and a wide selection of elegant bed frames that are practically indestructible (it's in the name, folks!), there's a lot to like about the brand as a whole.
Right now, Sleeping Duck is holding its EOFY sale with multiple offers to choose from. Its dreamiest offer, though, is on a sleep system that pairs the coveted SD Mach II mattress with an Indestruct bed frame, with savings of up to AU$789 on offer.
You'll need to act fast if you want to upgrade your bed and sleep sounder this winter — this deal is set to expire on July 7, 2025. If you're interested in the full list of discounted items, check out Sleeping Duck's EOFY storefront.
Sleeping Duck's biggest savings in its EOFY sale are exclusive to its SD sleep systems, with up to AU$789 off select Indestruct bed frames when bundled with the SD Mach II mattress. You'll need to add both items to the cart and apply the code EOFYSYSTEM25 to score the discount but, please note, the amount you save will depend on which bed frame you choose. The maximum AU$789 discount is only available for the Palais Super King Bed in Deep Luna Grey and the Super King SD Mach II mattress.
In our SD Mach II mattress review, we were thoroughly impressed, calling it "the best mattress-in-a-box we've had the pleasure of sleeping on". The biggest selling point of the SD Mach II is its adjustable firmness foam layer, which you can select between four options on the website before placing your order.
Once you receive the mattress, if you decide it's a little too soft (or firm) for your liking, you can choose a different foam layer and have it replaced for free during your trial window. All you'll need to do is swap out the appropriate layer, and hey, presto, you've got the ideal mattress. If you're undecided on what firmness level will suit you best, you can fill out SD's quiz on the website or contact their customer service for more information.
If you're more focused on the interior design standpoint, Sleeping Duck's Indestruct bed frames come in a variety of different colourways, sizes and styles. From majestic statement bedheads to minimalist frames, Sleeping Duck's range has something for every bedroom, including your kids'.
So, if you've wanted to upgrade your bed and mattress, there's no time like the present to shop the discounted offers at Sleeping Duck. The brand gets our seal of approval.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Cleo Diagnostics (ASX:COV) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. Given this risk, we thought we'd take a look at whether Cleo Diagnostics (ASX:COV) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Cleo Diagnostics last reported its December 2024 balance sheet in February 2025, it had zero debt and cash worth AU$7.3m. In the last year, its cash burn was AU$2.8m. That means it had a cash runway of about 2.6 years as of December 2024. That's decent, giving the company a couple years to develop its business. The image below shows how its cash balance has been changing over the last few years. Check out our latest analysis for Cleo Diagnostics While Cleo Diagnostics did record statutory revenue of AU$211k over the last year, it didn't have any revenue from operations. To us, that makes it a pre-revenue company, so we'll look to its cash burn trajectory as an assessment of its cash burn situation. During the last twelve months, its cash burn actually ramped up 58%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Cleo Diagnostics makes us a little nervous due to its lack of substantial operating revenue. So we'd generally prefer stocks from this list of stocks that have analysts forecasting growth. While Cleo Diagnostics does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Cleo Diagnostics' cash burn of AU$2.8m is about 5.4% of its AU$51m market capitalisation. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money. As you can probably tell by now, we're not too worried about Cleo Diagnostics' cash burn. For example, we think its cash runway suggests that the company is on a good path. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Based on the factors mentioned in this article, we think its cash burn situation warrants some attention from shareholders, but we don't think they should be worried. On another note, we conducted an in-depth investigation of the company, and identified 3 warning signs for Cleo Diagnostics (1 is a bit concerning!) that you should be aware of before investing here. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
2 days ago
- New York Post
Senate GOP sets ‘aspirational' Saturday vote for Trump's ‘big beautiful bill'
WASHINGTON — Senate Republicans will be working through the weekend to try to pass their 'big beautiful' tax-and-spending megabill, even as last-minute deals on provisions are still being worked out and holdouts remain. Senate Majority Leader John Thune (R-SD) announced Friday that an 'aspirational' vote Saturday at noon would kick off debating the revised multitrillion-dollar bill, after supporters were delivered a setback with the culling of hundreds of billions of dollars in Medicaid spending reforms earlier this week. The bill, which could pass with a simple majority through a process known as budget reconciliation, makes portions of President Trump's 2017 tax cuts permanent, ends taxation on tips and overtime, boosts border security funding and scraps green-energy tax credits passed in the last administration. But it will have to raise the debt ceiling by roughly $5 trillion in order to cram all the provisions in. 5 Senate Majority Leader John Thune (R-SD) announces Friday that an 'aspirational' vote Saturday at noon would kick off debating the multitrillion-dollar 'One Big Beautiful Bill.' AP With a 53-47 majority in the upper chamber, the GOP can only afford to lose three votes and still pass the package with a tie-breaking ballot cast by Vice President JD Vance. A final copy of the proposed legislation has yet to be released. A version of it passed the House by a single vote May 22. But the lower chamber will have to vote on the bill again after the Senate finalizes its changes to it. Trump had been hoping the bill would pass both chambers and reach his desk for signing by July 4. 'The Great Republicans in the U.S. Senate are working all weekend to finish our 'ONE, BIG, BEAUTIFUL BILL,'' the president posted on his Truth Social on Friday. 5 President Trump had been hoping it would reach his desk by July 4. 'The House of Representatives must be ready to send it to my desk before July 4th – We can get it done,' he also said, adding later: 'We can go longer, but we'd like to get it done by that time, if possible.' GOP momentum screeched to a halt Thursday as the Senate's 'parliamentarian,' Elizabeth MacDonough — the 'referee' of the chamber who ensures proposed legislation abides by the rules — threw out line items that would have eliminated health-care coverage for non-citizens. The provisions had run afoul of the so-called 'Byrd Rule' — named for former Senate Majority Leader Robert Byrd ( — which requires bills passed under reconciliation to only focus on changes to spending and revenue levels rather than policy. 5 Sen. Tommy Tuberville (R-Ala.) has fumed over setbacks to its passage. AP Sen. Tommy Tuberville (R-Ala.) called for MacDonough's firing in response, posting on X: 'This is a perfect example of why Americans hate THE SWAMP. 'The WOKE Senate Parliamentarian, who was appointed by Harry Reid and advised Al Gore, just STRUCK DOWN a provision BANNING illegals from stealing Medicaid from American citizens,' he fumed. McDonough, a career civil servant, was appointed to her post by Democrats in 2012. Some of the health-care spending reforms have posed an issue for centrist Sens. Lisa Murkowski (R-Alaska) and Susan Collins (R-Maine) as well as GOP Sens. Josh Hawley (Missouri) and Jerry Moran (Kansas). 5 Sen. Ron Johnson (R-Wis.) has criticized the bill's impact on the national deficit. CQ-Roll Call, Inc via Getty Images 5 Senate Republicans will be working through the weekend to try to pass their 'big beautiful' tax-and-spending megabill. AFP via Getty Images The libertarian-minded Sen. Rand Paul (R-Ky.) and Sen. Ron Johnson (R-Wis.) have also criticized the bill's impact on the national deficit: as much as $3 trillion over the next decade, according to projections provided by the Congressional Budget Office (CBO). The House-passed bill also increases the state and local tax (SALT) deduction from $10,000 to $40,000 over a five-year period, though that line item had been contested by some in the Senate until recently. House Speaker Mike Johnson (R-La.) told reporters Friday morning that progress had been made on the SALT issue at a Thursday night meeting of Treasury officials and SALT Republicans. 'No one will be delighted about it, but that's kind of the way this works around here,' Johnson said. 'But the other issues, I think, will be resolved, hopefully today, and we can move forward.' Additional reporting by Kendall White
Yahoo
2 days ago
- Yahoo
Regencell's 82,000% Surge: The $33 Billion Stock Rally That Nobody Can Explain
When Regencell Bioscience (NASDAQ:RGC) surged 82,000%, it wasn't on the back of a blockbuster drug or FDA approval. It was something far stranger. A small, loss-making traditional Chinese medicine firm with a vacant chief medical officer post and no revenue catalyst suddenly became a $33 billion paper giantat least for a few days. At the peak, founder and CEO Yat-Gai Au's stake eclipsed the wealth of Hong Kong's richest tycoons. He wasn't at the office. No press conference. No update. Then came the crash. As of June 26, the stock has fallen 74%, dragging Au's fortune down to $8.6 billion. Warning! GuruFocus has detected 2 Warning Signs with RGC. The company's fundamentals don't justify its viral rise. Regencell markets herbal formulas for ADHD and autism, developed by Au's father, under the trademark Brain Theory. It posted net losses of $4.4 million in fiscal 2024 and $6.1 million in 2023. Yet it managed to outshine every major healthcare brand on Instagramthanks in part to Taylor Swift ticket giveaways. Its second-largest shareholder? A firm tied to Zoom early investor Samuel Chen. Chen, along with his family, also controls Taiwan's Polaris Group and holds a major stake in IC firm Sonix Technology. None of them are talking. And neither is Regencell. Now regulators might start asking the questions retail investors already are. With no news, no insider filings, and no scientific breakthroughs, the stock's behavior has triggered interest from market observers. Both the SEC and Finra have automated tools for flagging anomalies like this, and experts say it's exactly the kind of movement that draws scrutiny. On June 4, the SEC even floated a proposal to tighten rules on foreign private issuerscompanies like Regencell that operate overseas but trade in the U.S. Whether the rally was driven by low float dynamics, social media virality, or something more problematic remains to be seen. But one thing's certain: for investors, this was a $33 billion lesson in how fast the music can stop. This article first appeared on GuruFocus. Sign in to access your portfolio
